Sign in
TerminatedEarly phase 1

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Key facts

Who runs it
Koo Foundation Sun Yat-Sen Cancer Center
Where
Taiwan4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Early phase 1
People taking part
12 people enrolled
Started
26 Jan 2021
Ended
9 Apr 2026
Type of study
Interventional
Treatments tested
  • IA therapy of HCC with CSR02-Fab-TF
Record updated
25 August 2026
Why it stopped
The decision has been made to terminate the study due to logistical reasons and not due to any safety concerns.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Diagnosis of HCC by at least one of the following criteria:; Histological confirmation; Magnetic resonance imaging (MRI) or computerized tomography (CT) consistent with liver cirrhosis AND at least one solid liver lesion > 1 cm with intense contrast uptake during the arterial phase followed by contrast washout during the venous phase regardless of alpha-fetal protein (AFP) level
  • Barcelona Clinic Liver Cancer (BCLC) Intermediate Stage B or limited Advanced Stage C (see Protocol Section 3.1). Patients with Stage C disease should have received or been offered and chosen not to receive systemic therapy
  • Inadequate response to prior liver-directed therapy (e.g., TACE, bland embolization, Y90, ablation, radiation therapy) to the same targeted area or progressive disease after prior liver-directed therapy) or to one or more systemic therapies
  • Not a candidate for curative resection, liver transplantation, or percutaneous ablation (See Protocol Appendix 3)
  • Eastern Collective Oncology Group (ECOG) performance status ≤1 (See Protocol Appendix 5)
  • Adequate laboratory parameters, including:; Serum total bilirubin ≤ 2x ULN; Alkaline phosphatase, aspartate aminotransferase (AST) and aspartate aminotransferase (ALT) < 5 x ULN; Serum creatinine ≤ 1.5 mg/dL; Prothrombin time (international normalized ratio; INR) ≤ 1.5; Absolute neutrophil count > 1000/μL; Platelet count > 75,000/μL; Hgb > 8 g/dL
  • Acceptable pulmonary status, including room air O2 saturation > 90%
  • Child-Pugh A-B7 without clinically significant ascites (See Protocol Appendix 4)
  • Signed informed consent
  • All subjects must be surgically sterile, at least two years post-menopausal (if female), or agree to use adequate, effective contraception approved by the Investigator until two (2) months after receiving a final dose of CSR02-Fab-TF

Who cannot take part

  • Eligible for transplantation by Milan criteria (Protocol Appendix 3) or potentially eligible if successfully "down staged" by pre-transplant therapy
  • Prior organ transplantation
  • Any small molecule drug treatment for HCC (including TACE) within the previous 30 days, treatment with biological agents or any investigational therapy within the previous 60 days, or treatment with Y90 within the previous 90 days
  • Previously treated malignancies from which the subject has not been disease-free for at least 2 years, except for adequately treated non-melanoma skin cancer, in situ cancer, or low-grade prostate or bladder cancer
  • New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial infarction within 3 months prior to therapy, unstable arrhythmia, symptomatic peripheral arterial vascular disease, or presence of an artificial or other vascular device requiring chronic anticoagulation (See Protocol Appendix 6)
  • Major surgery, vascular injury, or serious illness within the previous 60 days
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy at screening. Subjects with prior HBV (positive HBSAg) must have HBV viral load < 2000 IU/mL or be receiving concurrent anti-HBV therapy to be eligible. Subjects on anti-HBV therapy must have been on treatment with a viral load maintained at < 2000 IU/mL for at least 4 weeks prior to first dose and continue on this same therapy throughout study treatment. Subjects with HCV infection are eligible if other eligibility criteria are met
  • Therapeutic anticoagulation that cannot be stopped 24-72 hours before treatment (per Section 4.5) and reinstituted no sooner than 72 hours after therapy
  • Any concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study
  • Severe chronic obstructive or other pulmonary disease with hypoxemia that requires supplementary oxygen or clinically significant pleural effusions
  • Known inherited thrombophilia (hypercoagulable state) or history of unprovoked venous or arterial thrombosis
  • Allergy to iodinated contrast medium that is uncontrolled or refractory to medical therapy
  • Any of the following risks related to QT/QTc interval:; Baseline prolongation of QT/QTc interval (repeated interval > 480 milliseconds using Frederica's QT correction formula); History of additional risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of Long QT syndrome); Concomitant medications that have a known risk for prolongation of the QT/QTc interval (see https://crediblemeds.org/new-drug-list/)
  • Females who are breast-feeding
  • Unwillingness or inability to comply with the study protocol for any reason

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of the fact that the blood supply of HCC comes predominantly from the hepatic artery compared with the surrounding normal liver which is predominantly supplied by portal venous blood. The intent is to deprive the HCC of its blood supply, leading to the death of the tumor. Traditionally, various methods have been used to block the HCC blood supply, but improvements are needed. This study will investigate a new agent designed in the laboratory to block only tumor blood vessels, not blood vessels in the normal liver.

The group in the trial

  • Investigational ArmTreatment being tested

    Treatment: IA therapy of HCC with CSR02-Fab-TF

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CSR02-Fab-TF as Hepatic Intra-arterial Therapy in Intermediate Stage B or Limited Advanced Stage C Hepatocellular Carcinoma (HCC): Dose-Escalation Study to Assess Safety and Tolerability
Record updated
25 August 2026